Gene Therapy Commercial Viability: From Approval to Patient Access | LeverVenture

Regulatory approval is where most gene therapy investment theses stop underwriting risk and start underwriting return. That is the mistake. Manufacturing capacity, site-of-care concentration, a reimbursement architecture built for chronic therapy rather than a single infusion, and the unresolved question of how long a one-time treatment actually lasts are all risks that begin, rather than end, at approval. Commercial viability in gene therapy is a separate discipline from clinical success, with its own failure modes, and it deserves its own underwriting line.

The clearest evidence is the growing list of approved gene and cell therapies that have underperformed their addressable patient populations by a wide margin — not because the science failed, but because the machinery required to manufacture, distribute, pay for, and track the therapy could not keep pace with the approval. A company that has solved the biology has solved the harder scientific problem. It has not necessarily solved the easier-sounding, actually-harder commercial one.

01Manufacturing Capacity Sets the Real Ceiling

Most gene and cell therapies depend on viral vector production or patient-specific cell processing, both of which are capital-intensive, slow to scale, and concentrated in a small number of contract development and manufacturing organizations. A company can hold an approved product and still be capacity-constrained for years, because vector manufacturing lines cannot be stood up overnight and quality failures in a single production run can consume months of output. Investors who underwrite a launch curve based on addressable patient population alone are assuming manufacturing capacity that may not exist on the company's timeline.

This is measurable in diligence in a way clinical risk often is not: a company's manufacturing strategy — in-house capacity versus CDMO reliance, the number of qualified production sites, batch failure history — is disclosable and comparable across companies well before launch.

02Site-of-Care Concentration Is a Distribution Problem, Not a Marketing One

Administering a gene therapy typically requires a qualified treatment center with specialized infusion or apheresis capability, trained staff, and in many cases proximity to a manufacturing or conditioning protocol with a narrow time window. That concentrates delivery into a small number of centers of excellence, often academic medical centers, which creates real geographic and capacity bottlenecks independent of demand. A therapy can be fully reimbursed and still reach only the fraction of eligible patients who live near, or can travel to, one of the handful of sites equipped to deliver it.

A gene therapy is not commercially viable because it is approved. It is commercially viable when a patient who needs it can actually receive it, from a center that can actually deliver it, paid for by a system built to pay for it.

03Reimbursement Was Built for Recurring Cost, Not a Cure

A Payment System Mismatch

Most reimbursement infrastructure in the United States was built around recurring costs — a chronic medication taken for years, a device replaced on a schedule. A gene therapy inverts that: a single, very large payment intended to replace years of ongoing treatment cost, with the clinical and financial benefit realized over a time horizon that outlasts a typical health plan's enrollment of that patient. That mismatch is a structural payer problem, not a pricing dispute, and it shows up as slow formulary adoption, prior authorization friction, and payer reluctance even when the underlying health economics genuinely favor the therapy.

Public payers have begun building purpose-built mechanisms to address exactly this gap. The Center for Medicare and Medicaid Innovation's Cell and Gene Therapy Access Model, built for sickle cell disease gene therapies, has state Medicaid programs opt into a common outcomes-based agreement framework with the manufacturers rather than negotiating bespoke terms state by state. It is a direct acknowledgment that the standard reimbursement architecture did not fit this category of product, and that fixing it required a new mechanism rather than a workaround. Commercial payers have watched this model closely, because the same structural mismatch exists in commercial insurance, just without a single national convener to standardize the fix.

Outcomes-Based Contracts Solve the Payment Problem and Create a New Data Problem

An outcomes-based agreement ties some portion of the payment to whether the therapy actually delivers the expected result over time, with a manufacturer rebate obligation if it does not. This aligns incentives correctly, but it requires infrastructure most biotech companies have never had to build: long-horizon patient registries, agreed-upon outcome definitions, and the administrative capacity to track and reconcile claims against those definitions for years after the point of sale. A company can have a well-structured outcomes-based deal on paper and still fail to execute it if the underlying evidence infrastructure is not built and funded from launch. That infrastructure is itself a commercial asset worth underwriting separately from the therapy — a company that has already built its outcomes registry ahead of launch has removed one of the more common execution failures in this category.

04Durability of Effect Is the Risk That Never Fully Resolves

Approval trials, by necessity, follow patients for a fraction of the duration over which a "one-time cure" claim is being made. Durability risk — whether the therapeutic effect persists for the years or decades implied by the pricing and the payment structure — does not close out at approval. It is carried by the company, the payer, and ultimately the patient for as long as the therapy is on the market, and every outcomes-based contract, every long-term follow-up study, and every post-market surveillance requirement exists because that question has not been fully answered by the time the product launches.

05The Commercial Risk Stack

06Underwriting the Gap Between Approval and Access

Growth equity investors evaluating a gene therapy company at or near approval should treat manufacturing, distribution, reimbursement, and durability as four distinct diligence workstreams, each with its own evidence and its own failure mode, rather than folding them into a single generic "commercialization risk" line. The company with the stronger data package is not necessarily the one that reaches the most patients fastest; the company with a funded manufacturing plan, contracted treatment centers, and a real outcomes-based reimbursement strategy already in motion is. For how this connects to the broader diagnostics and access question in oncology, see our note on the diagnostic bottleneck in precision oncology, and for how regulatory strategy interacts with product roadmap more broadly, see FDA digital health guidance.

Nothing in this piece is investment, legal, tax or accounting advice, and nothing in it is an offer to sell or a solicitation of an offer to buy any security.

Peleg Chevion

Managing Partner

Three decades of operational leadership across agriculture, pharmaceuticals, biotechnology, climate, food and defense. He has spent that career doing the work this seat requires: strategic partnerships, licensing and business development, executed transaction by transaction. He sits with a company as an operating partner and a growth strategist rather than as a name on its board. A corporate finance and intellectual property attorney, an INSEAD MBA, and a former Air Force officer in aerospace. He also brings strong private equity experience.

Full profile

Send a message